Single high-dose recombinant human granulocyte-macrophage colony stimulating factor: results of a phase I tolerability study.
Dieterle
A
A
Division of Oncology, University Kantonsspital, Basel, Switzerland.
Gratwohl
A
A
Ritz
R
R
Obrecht
J P
JP
Obrist
R
R
D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D005334:Fever / Q000139:chemically induced; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008875:Middle Aged; D008991:Monitoring, Physiologic; D009369:Neoplasms / Q000097:blood / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood
D011994:Recombinant Proteins; D016178:Granulocyte-Macrophage Colony-Stimulating Factor